scholarly journals Pediatric lung imaging features of COVID‐19: A systematic review and meta‐analysis

2020 ◽  
Vol 56 (1) ◽  
pp. 252-263
Author(s):  
Gustavo Nino ◽  
Jonathan Zember ◽  
Ramon Sanchez‐Jacob ◽  
Maria J. Gutierrez ◽  
Karun Sharma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Lung Imaging ◽  
Imaging Features

Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

2014 ◽  
Vol 23 (8) ◽  
pp. 1464-1483 ◽  
Author(s):  
Sjoerd G. Elias ◽  
Arthur Adams ◽  
Dorota J. Wisner ◽  
Laura J. Esserman ◽  
Laura J. van't Veer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Her2 Overexpression ◽  
Imaging Features

scholarly journals Prenatal imaging features and postnatal outcomes of isolated fetal duplex renal collecting system: A systematic review and meta‐analysis

2020 ◽  
Vol 40 (4) ◽  
pp. 424-431
Author(s):  
Francesca Bascietto ◽  
Asma Khalil ◽  
Giuseppe Rizzo ◽  
Alexander Makatsariya ◽  
Danilo Buca ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Imaging Features ◽  
System A ◽  
Prenatal Imaging ◽  
Collecting System

scholarly journals Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

2020 ◽  
Vol 34 ◽  
pp. 101623 ◽  
Author(s):  
Alfonso J. Rodriguez-Morales ◽  
Jaime A. Cardona-Ospina ◽  
Estefanía Gutiérrez-Ocampo ◽  
Rhuvi Villamizar-Peña ◽  
Yeimer Holguin-Rivera ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Laboratory ◽  
Meta Analysis ◽  
Imaging Features

scholarly journals Correction: Imaging features of intracerebral hemorrhage with cerebral amyloid angiopathy: Systematic review and meta-analysis

PLoS ONE ◽  
2017 ◽  
Vol 12 (10) ◽  
pp. e0187386
Author(s):  
Neshika Samarasekera ◽  
Mark Alexander Rodrigues ◽  
Pheng Shiew Toh ◽  
Rustam Al-Shahi Salman
Keyword(s):  
Systematic Review ◽  
Intracerebral Hemorrhage ◽  
Cerebral Amyloid Angiopathy ◽  
Meta Analysis ◽  
Amyloid Angiopathy ◽  
Imaging Features ◽  
Cerebral Amyloid

scholarly journals Leptomeningeal Enhancement in Multiple Sclerosis and Other Neurological Diseases: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Benjamin Victor Ineichen ◽  
Charidimos Tsagkas ◽  
Martina Absinta ◽  
Daniel S Reich
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Neurological Diseases ◽  
Meta Analysis ◽  
Mean Difference ◽  
Clinical Settings ◽  
Imaging Features ◽  
Qualitative Synthesis ◽  
Leptomeningeal Enhancement ◽  
Relapsing Remitting

Background: The lack of systematic evidence on leptomeningeal enhancement (LME) on MRI in neurological diseases, including multiple sclerosis (MS), hampers its interpretation in clinical routine and research settings. Purpose: To perform a systematic review and meta-analysis of MRI LME in MS and other neurologi-cal diseases. Materials and Methods: In a comprehensive literature search in Medline, Scopus, and Embase, out of 2292 publications, 459 records assessing LME in neurological diseases were eligible for qualitative synthesis. Of these, 135 were included in a random effects model meta-analysis with subgroup analyses for MS. Results: Of eligible publications, 161 investigated LME in neoplastic neurological (n=2392), 91 in neuroinfectious (n=1890), and 75 in primary neuroinflammatory diseases (n=4038). The LME proportions for these disease classes were 0.47 [95%CI: 0.37 to 0.57], 0.59 [95%CI: 0.47 to 0.69], and 0.26 [95%CI: 0.20 to 0.35], respectively. In a subgroup analysis comprising 1605 MS cases, LME proportion was 0.30 [95%CI 0.21 to 0.42] with lower proportions in relapsing-remitting (0.19 [95%CI 0.13 to 0.27]) compared to progressive MS (0.39 [95%CI 0.30 to 0.49], p=0.002) and higher proportions in studies imaging at 7T (0.79 [95%CI 0.64 to 0.89]) compared to lower field strengths (0.21 [95%CI 0.15 to 0.29], p<0.001). LME in MS was associated with longer disease duration (mean difference 2.2 years [95%CI 0.2 to 4.2], p=0.03), higher Expanded Disability Status Scale (mean difference 0.6 points [95%CI 0.2 to 1.0], p=0.006), higher T1 (mean difference 1.6ml [95%CI 0.1 to 3.0], p=0.04) and T2 lesion load (mean difference 5.9ml [95%CI 3.2 to 8.6], p<0.001), and lower cortical volume (mean difference -21.3ml [95%CI -34.7 to -7.9], p=0.002). Conclusions: Our study provides high-grade evidence for the substantial presence of LME in MS and a comprehensive panel of other neurological diseases. Our data could facilitate differential diagnosis of LME in clinical settings. Additionally, our meta-analysis corroborates that LME is associ-ated with key clinical and imaging features of MS. PROSPERO No: CRD42021235026.

scholarly journals The Novel Coronavirus Disease (COVID-19): A PRISMA Systematic Review and Meta-Analysis of Clinical and Paraclinical Characteristics

2020 ◽  
Vol 2020 ◽  
pp. 1-16 ◽  
Author(s):  
Hamidreza Hasani ◽  
Shayan Mardi ◽  
Sareh Shakerian ◽  
Nooshin Taherzadeh-Ghahfarokhi ◽  
Parham Mardi
Keyword(s):  
Systematic Review ◽  
Observational Studies ◽  
Clinical Laboratory ◽  
Meta Analysis ◽  
Ct Scanning ◽  
Imaging Features ◽  
The Novel ◽  
Laboratory Findings ◽  
Global Concern ◽  
Novel Coronavirus

An outbreak of pneumonia, caused by a novel coronavirus (SARS-CoV-2), was identified in China in December 2019. This virus expanded worldwide, causing global concern. Although clinical, laboratory, and imaging features of COVID-19 are characterized in some observational studies, we undertook a systematic review and meta-analysis to assess the frequency of these features. We did a systematic review and meta-analysis using three databases to identify clinical, laboratory, and computerized tomography (CT) scanning features of rRT-PCR confirmed cases of COVID-19. Data for 3420 patients from 30 observational studies were included. Overall, the results showed that fever (84.2%, 95% CI 82.6-85.7), cough (62%, 95% CI 60-64), and fatigue (39.4%, 95% CI 37.2-41.6%) are the most prevalent symptoms in COVID-19 patients. Increased CRP level, decreased lymphocyte count, and increased D-dimer level were the most common laboratory findings. Among COVID-19 patients, 92% had a positive CT finding, most prevalently ground-glass opacification (GGO) (60%, 95% CI 58-62) and peripheral distribution opacification (64%, 95% CI 60-69). These results demonstrate the clinical, paraclinical, and imaging features of COVID-19.

Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis

2018 ◽  
Vol 129 (2) ◽  
pp. 196-208 ◽  
Author(s):  
Nicholas W. Bucknell ◽  
Nicholas Hardcastle ◽  
Mathias Bressel ◽  
Michael S. Hofman ◽  
Tomas Kron ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Radiation Therapy ◽  
Meta Analysis ◽  
Lung Imaging ◽  
Functional Lung Imaging

scholarly journals Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Catherine Ruth Jutzeler ◽  
Lucie Bourguignon ◽  
Caroline V. Weis ◽  
Bobo Tong ◽  
Cyrus Wong ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Publication Bias ◽  
Meta Analysis ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Imaging Features ◽  
Laboratory Findings ◽  
Clinical Signs And Symptoms ◽  
Meta Analyses

Introduction Since December 2019, a novel coronavirus (SARS-CoV-2) has triggered a world-wide pandemic with an enormous medical, societal, and economic toll. Thus, our aim was to gather all available information regarding comorbidities, clinical signs and symptoms, outcomes, laboratory findings, imaging features, and treatments in patients with coronavirus disease 2019 (COVID-19). Methods EMBASE, PubMed/ Medline, Scopus, and Web of Science were searched for studies published in any language between December 1st, 2019 and March 28th. Original studies were included if the exposure of interest was an infection with SARS-CoV-2 or confirmed COVID-19. The primary outcome was the risk ratio of comorbidities, clinical signs and symptoms, imaging features, treatments, outcomes, and complications associated with COVID-19 morbidity and mortality. We performed random-effects pairwise meta-analyses for proportions and relative risks, I2, Tau2, and Cochrane Q, sensitivity analyses, and assessed publication bias. Results: 148 met the inclusion criteria for the systematic review and meta-analysis with 12149 patients (5739 female) and a median age was 47.0 [35.0-64.6]. 617 patients died from COVID-19 and its complication, while 297 patients were reported as asymptomatic. Older age (SMD: 1.25 [0.78- 1.72]; p < 0.001), being male (RR = 1.32 [1.13-1.54], p = 0.005) and pre-existing comorbidity (RR = 1.69 [1.48-1.94]; p < 0.001) were identified as risk factors of in-hospital mortality. The heterogeneity between studies varied substantially (I2; range: 1.5-98.2%). Publication bias was only found in eight studies (Eggers test: p < 0.05). Conclusions: Our meta-analyses revealed important risk factors that are associated with severity and mortality of COVID-19.

Sign in / Sign up

Export Citation Format

Share Document